UTHR: Aggressive product launches and innovation aim for $50—100B revenue and industry leadership
Fourteen new products are set for rapid launch, targeting $50—100 billion in annual pharma revenue and addressing a million-patient market. Key innovations include once-daily and coughless inhalers, with strong IP protection and major investments in manufacturing and xenotransplantation.Based on Un…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.